StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $21.81 | $20.25 | -7.15% | 2.9M |
| 05-12 | $20.25 | $19.94 | -1.53% | 1.7M |
| 05-13 | $20.21 | $19.85 | -1.78% | 1.6M |
| 05-14 | $19.73 | $19.01 | -3.65% | 1.7M |
| 05-15 | $18.76 | $17.74 | -5.44% | 1.5M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 |
|---|---|---|---|---|
Revenue | $59.00K | $0.00 | $441.00K | $249.00K |
Operating Income | $-72.92M | $-53.18M | $-68.51M | $-55.20M |
Net Income | $-78.26M | $-64.54M | $-35.13M | $210.00K |
EPS (Diluted) | $-5.84 | $-5.47 | $-20.91 | $-22.63 |
Total Assets | $116.46M | $125.10M | $150.73M | $98.45M |
Total Liabilities | $33.41M | $33.55M | $17.70M | $75.72M |
Cash & Equivalents | $15.86M | $26.96M | $134.55M | $81.86M |
Free Cash Flow OCF − CapEx | Not available | Not available | $-49.06M | $-34.01M |
Shares Outstanding | 18.51M | 17.83M | 10.47M | 9.68M |
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.